Research article

Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide

Keiichi Iwanami1, Isao Matsumoto1,2, Yohei Yoshiga1, Asuka Inoue1, Yuya Kondo1, Kayo Yamamoto1, Yoko Tanaka1, Reiko Minami1, Taichi Hayashi1, Daisuke Goto1, Satoshi Ito1, Yasuharu Nishimura3 and Takayuki Sumida1

1Department of Clinical Immunology, Doctoral Program in Clinical Science, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba 305-8575, Japan
2PRESTO, Japan Science and Technology Agency, 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
3Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, 2-39-1 Kurokami, Kumamoto 860-8556, Japan

Corresponding author: Isao Matsumoto, ismatsu@md.tsukuba.ac.jp

Received: 4 May 2009 Revisions requested: 2 Jul 2009 Revisions received: 23 Sep 2009 Accepted: 9 Nov 2009 Published: 9 Nov 2009

Arthritis Research & Therapy 2009, 11:R167 (doi:10.1186/ar2854)

This article is online at: http://arthritis-research.com/content/11/6/R167

© 2009 Iwanami et al.; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction Immunosuppressants, including anti-TNFα antibodies, have remarkable effects in rheumatoid arthritis; however, they increase infectious events. The present study was designed to examine the effects and immunological change of action of altered peptide ligands (APLs) on glucose-6-phosphate isomerase (GPI) peptide-induced arthritis.

Methods DBA/1 mice were immunized with hGPI325-339 and cells of draining lymph node (DLN) were stimulated with hGPI325-339 to investigate the T-cell receptor (TCR) repertoire of antigen-specific CD4+ T cells by flow cytometry. Twenty types of APLs with one amino acid substitution at a TCR contact site of hGPI325-339 were synthesized. CD4+ T cells primed with human GPI and antigen-presenting cells were co-cultured with each APL and cytokine production was measured by ELISA to identify antagonistic APLs. Antagonistic APLs were co-immunized with hGPI325-339 to investigate whether arthritis could be antigen-specifically inhibited by APL. After co-immunization, DLN cells were stimulated with hGPI325-339 or APL to investigate Th17 and regulatory T-cell population by flow cytometry, and anti-mouse GPI antibodies were measured by ELISA.

Results Human GPI325-339-specific Th17 cells showed predominant usage of TCRVβ8.1 8.2. Among the 20 synthesized APLs, four (APL 6; N329S, APL 7; N329T, APL 12; G332A, APL 13; G332V) significantly reduced IL-17 production by CD4+ T cells in the presence of hGPI325-339. Co-immunization with each antagonistic APL markedly prevented the development of arthritis, especially APL 13 (G332V). Although co-immunization with APL did not affect the population of Th17 and regulatory T cells, the titers of anti-mouse GPI antibodies in mice co-immunized with APL were significantly lower than in those without APL.

Conclusions We prepared antagonistic APLs that antigen-specifically inhibited the development of experimental arthritis. Understanding the inhibitory mechanisms of APLs may pave the way for the development of novel therapies for arthritis induced by autoimmune responses to ubiquitous antigens.

Introduction

Rheumatoid arthritis (RA) is characterized by symmetrical polyarthritis and joint destruction. Although the etiology is considered autoimmune reactivity to some antigens, the exact mechanisms are not fully understood. Pathological examinations show that most of the lymphocytes infiltrating the synovium in RA are CD4+ T cells, which can recognize some antigens and expand oligoclonally intraarticularly [1]. These findings imply the possible role of CD4+ T cells in the pathogenesis of RA. Previous studies showed that cytotoxic T-lymphocyte antigen-4 immunoglobulin and tacrolimus have remarkable effects on RA, and stressed the importance of CD4+ T cells in the pathogenesis of RA [2-4].

Ab: antibody; APC: antigen-presenting cell; APL: altered peptide ligand; CII: collagen type II; DLN: draining lymph node; ELISA: enzyme-linked immunosorbent assay; GPI: glucose-6-phosphate isomerase; IFN: interferon; IL: interleukin; MBP: myelin basic protein; MHC: major histocompatibility complex; PBS: phosphate-buffered saline; PLP: proteolipid protein; RA: rheumatoid arthritis; rhGPI: recombinant human glucose-6-phosphate isomerase; TCR: T-cell receptor; Th: T-helper; TNF: tumor necrosis factor.
Although the exact helper T-cell lineage critical in RA remains elusive, previous animal studies reported that Th17 cells play a crucial role and that Th1 cells may have a protective role against the progress of arthritis in most mouse models with the exception of proteoglycan-induced arthritis in Balb/c mice [5]. Collagen-induced arthritis in the C57BL/6 background is markedly suppressed in IL-17-deficient mice [6], and glucose-6-phosphate isomerase (GPI)-induced arthritis in the DBA/1 background and antigen-induced arthritis in the C57BL/6 background are also suppressed by the administration of anti-IL-17 antibodies (Abs) [7,8]. In these models, complete Freund’s adjuvant is used for the induction of arthritis; therefore it is possible that the components of Mycobacterium tuberculosis affect the cytokine dependency. The arthritis seen in IL-1 receptor antagonist-deficient mice in the Balb/c background and SKG mice in the Balb/c background, however, is completely suppressed in IL-17-deficient mice [9,10]. These findings indicate that Th17 cells play a central role in murine models independent of mouse strains and target antigens.

IL-17 is also considered to play a crucial role in host defense. IL-17 signaling seems essential for the recruitment of neutrophils to the alveolar space in pneumonia caused by Klebsiella pneumoniae, Mycoplasma pneumoniae and Pneumocystis jiroveci [11-13]. IL-17 is also involved in mucosal host defense against oropharyngeal candidiasis via salivary antimicrobial factors, in addition to neutrophil recruitment [14]. Furthermore, IL-17 production by γδ T cells is essential against peritonitis caused by Escherichia coli [15]. In this regard, anti-cytokine therapies such as infliximab and tocilizumab have been applied to clinical treatment and have shown striking effects on RA [16-19]; anti-IL-17 therapy could be useful in the treatment of arthritis. Our analysis of the inhibitory mechanisms of APLs indicates that our APLs can function as TCR antagonists; however, they can differentiate naïve CD4+ T cells to Th17 cells, but not Th2 cells or regulatory T cells. Based on these findings, we define a new aspect for APLs, and propose that they may provide the basis for the invention of new antigen-specific therapy.

The present work is an extension to the above studies. Specifically, we explored the antigen-specific Th17 inhibition, explored the effects of APLs on arthritis, and investigated the inhibitory mechanisms of APLs, using the T-cell-dependent model of GPI peptide-induced arthritis. The results showed that many hGPI325-339-specific CD4+ T cells employed Vβ8.1.2 as the TCR repertoire, and co-immunization with APL (N329S, N329T, G332A, or G332V) significantly inhibited the development of arthritis. Our analysis of the inhibitory mechanisms of APLs indicates that our APLs can function as TCR antagonists; however, they can differentiate naïve CD4+ T cells to Th17 cells, but not Th2 cells or regulatory T cells. Based on these findings, we define a new aspect for APLs, and propose that they may provide the basis for the invention of new antigen-specific therapy.

Materials and methods

Mice

DBA/1 mice were purchased from Charles River Laboratories, Yokohama, Japan. All mice were kept under specific pathogen-free conditions, and all experiments were conducted in accordance with the institutional ethical guidelines.

Glucose-6-phosphate isomerase and synthetic peptides

The rhGPI and recombinant mouse GPI were prepared as described previously [28,29]. Briefly, human or mouse GPI cDNA was inserted into the plasmid pGEX-4T3 (Pharmacia, Uppsala, Sweden) for expression of glutathione-S-transferase-tagged proteins. E. coli harboring pGEX-hGPI plasmid was allowed to proliferate at 37°C, before the addition of 0.1 mM isopropyl-β-d-thiogalactopyranoside to the medium, followed by further culture overnight at 30°C. The bacteria were lysed with a sonicator and the supernatant was purified with a glutathione-Sepharose column (Pharmacia). The purity was estimated by SDS-PAGE.
Peptides for screening were synthesized with 70% purity by Wako Pure Chemical Industries, Ltd (Osaka, Japan), and peptides of a major peptide and antagonistic altered peptide ligands were synthesized with 90% purity by Invitrogen (Carlsbad, CA, USA). OVA232-339 peptide was purchased from AnaSpec (San Jose, CA, USA).

**Induction of arthritis**

DBA/1 mice were immunized with 10 μg synthetic peptides for GPI peptide-induced arthritis in complete Freund’s adjuvant (Difco Laboratories, Detroit, MI, USA), and in the indicated experiments 50 μg altered peptide ligands were used with 10 μg GPI325-339 for co-immunization. The synthetic peptides were emulsified with complete Freund’s adjuvant at a 1:1 ratio (v/v). For induction of arthritis, 150 μl emulsion was injected intradermally at the base of the tail, and 200 ng pertussis toxin was injected intraperitoneally on days 0 and 2 after immunization.

The arthritis score was evaluated visually using a score of 0 to 3 for each paw. A score of 0 represented no evidence of inflammation, 1 represented subtle inflammation or localized edema, 2 represented easily identified swelling that was localized to either the dorsal or ventral surface of the paws, and 3 represented swelling in all areas of the paws.

**Screening of antagonistic altered peptide ligands**

Mice were sacrificed on the indicated day. Spleens and draining lymph nodes (DLNs) were harvested, and splenocytes were hemolyzed with a solution of 0.83% NH₄Cl, 0.12% NaHCO₃ and 0.004% EDTA·Na in PBS. Single-cell suspensions were prepared in RPMI 1640 medium (Sigma-Aldrich, St Louis, MO, USA) containing 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 50 μM 2-mercaptopetoethanol. CD4⁺ T cells from DLNs and CD11c⁺ dendritic cells from spleens were isolated by magenetic-activated cell sorting (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of the collected cells (>97%) was confirmed by flow cytometry. CD11c⁺ dendritic cells treated with 50 μg/ml mitomycin C were used as antigen-presenting cells (APCs). The purified CD4⁺ T cells and APCs were co-cultured with 10 μM synthetic peptide at a ratio of 1:3 in 96-well round-bottom plates (Nunc, Roskilde, Denmark) at 37°C under 5% carbon dioxide for 72 hours. The supernatants were assayed for IL-10 and IL-17 by the Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA).

**Pre-pulse assay**

The pre-pulse assay was conducted as described previously [30]. Briefly, CD11c⁺ APCs from spleens (4 × 10⁶/well) were cultured with a suboptimal concentration of GPI325-339 (3 μM) for 2 hours. In the meantime, native peptides were loaded onto APCs and presented on MHC. After 2 hours of incubation, APCs were washed twice to remove unbound peptides, and 30 μM each antagonistic APL was added. After 18 hours of culture, CD4⁺ T cells (2 × 10⁶/well) from DLNs were added, and after an additional 72 hours of culture the supernatants were assayed for IL-17 and IL-10 by ELISA. The inhibition ratio was calculated as follows:

1 – (IL-17 concentration in the presence of native peptides and APLs / IL-17 concentration in the presence of native peptides only) x 100 (%)

**Flow cytometry**

Mice were sacrificed on the indicated day. The popliteal lymph nodes were harvested and single-cell suspensions were prepared as described above. Cells (1 × 10⁶/ml) were stimulated with 100 μg/ml rhGPI in 96-well round-bottom plates (Nunc) for 24 hours and GoldiStop (BD PharMingen, San Diego, CA, USA) was added for the last 2 hours of each culture. Cells were first stained extracellularly, fixed and permeabilized with Cytotix/Cytoperm solution (BD PharMingen) and then stained intracellularly. Regulatory T cells were stained with the Mouse Regulatory T Cell Staining kit (eBioscience, San Diego, CA, USA) according to the protocol supplied by the manufacturer. For TCR repertoire screening, the Mouse TCR Screening Panel (BD PharMingen) was used. Samples were acquired on FACSCalibur (BD PharMingen) and data were analyzed with FlowJo (Tree Star, Ashland, OR, USA).

**Analysis of anti-glucose-6-phosphate isomerase antibody**

Sera were taken from immunized mice on day 28 and were diluted 1:500 (for IgG, IgG₂a, IgG₂b and IgG₃) or 1:8,000 (for IgG₁) in blocking solution (25% Block Ace (Dainippon Sumitomo Pharma, Osaka, Japan) in PBS) for antibody analysis. We also prepared 96-well plates (Sumitomo Bakelite, Tokyo, Japan) coated with 5 μg/ml recombinant mouse GPI for 12 hours at 4°C. After washing twice with a washing buffer (0.05% Tween20 in PBS), the blocking solution was used for blocking nonspecific binding for 2 hours at room temperature. After two washes, 150 μl diluted serum was added and incubated for 2 hours at room temperature. After three washes, alkaline phosphatase-conjugated anti-mouse IgG, horseradish peroxidase-conjugated anti-mouse IgG₁, IgG₂a, IgG₂b (Zymed Laboratories, San Francisco, CA, USA) or IgG₃ (Invitrogen) was added at a final dilution of 1:5,000 for 1 hour at room temperature. After three washes, color was developed with substrates solution (1 alkaline phosphatase tablet (Sigma-Aldrich) per 5 ml alkaline phosphatase reaction solution (containing 9.6% diethanolamine and 0.25 mM MgCl₂, pH 9.8)) or tetramethylbenzidine (KPL, Gaithersburg, MD, USA). Plates were incubated for 20 to 60 minutes at room temperature and the optical density was measured by a microplate reader at 405 nm (for IgG) or at 450 nm (for IgG₁, IgG₂a, IgG₂b, and IgG₃).

**Statistical analysis**

All data are expressed as the mean ± standard error of the mean or standard deviation. Differences between groups were
examined for statistical significance using the Mann-Whitney U test. Differences of arthritis incidence between groups were examined using Fisher’s exact test. P < 0.05 denotes the presence of a statistically significant difference.

Results
Designing and screening antagonistic altered peptide ligands
We reported previously that the major T-cell epitope in GPI-induced arthritis is hGPI 325-339, and immunization with the peptide provokes symmetrical polyarthritis (GPI peptide-induced arthritis) [28]. To investigate the effects of APLs in GPI peptide-induced arthritis, we first designed APLs of hGPI 325-339. Since the MHC binding sites of hGPI 325-339 exist at P1 (I328), P4 (F331), and P7 (E334) (IWYINC-FGCETHAML) [25,28], the amino acid residues of the TCR contact sites at P0 (Y327), P2 (N329), P3 (C330), P5 (G332), P6 (C333), and P8 (T335) were substituted for another peptide to design 20 types of APLs (Table 1).

To select antagonistic APLs, CD4+ T cells primed with rhGPI and APCs were co-cultured with each APL. The IL-17 production was markedly lower with APL 2, APL 5, APL 6, APL 7, APL 9, APL 10, APL 11, APL 12, APL 13, and APL 18 than with hGPI 325-339, and therefore these APLs were considered candidates of antagonistic APLs (Figure 1a). None of the APLs induced IL-4 and IL-10 production (data not shown). We next explored the potency of the APLs in inhibiting IL-17 production in the presence of hGPI 325-339. In the pre-pulse assay, APL 6 (N329S), APL 7 (N329T), APL 12 (G332A), and APL 13 (G332V) significantly reduced IL-17 production by CD4+ T cells primed with rhGPI in the presence of hGPI 325-339 (P < 0.01) (Figure 1b). We therefore considered these four APLs as antagonistic APLs.

Inhibition of arthritis by antagonistic altered peptideligands
Since GPI peptide-induced arthritis is mediated by Th17 and antagonistic APLs can suppress IL-17 production, we explored the efficacy of the prepared APLs on the inhibition of

Table 1

| hGPI 325-339-derived altered peptide ligands used in the present study |
|--------------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 325 to 339 | I  | W  | Y  | I  | N  | C  | F  | G  | C  | E  | T  | H  | A  | M  | L  |
| APL 1  | -- | -- | N  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 2  | -- | -- | Q  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 3  | -- | -- | S  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 4  | -- | -- | T  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 5  | -- | -- | Q  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 6  | -- | -- | S  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 7  | -- | -- | T  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 8  | -- | -- | -- | N  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 9  | -- | -- | -- | Q  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 10 | -- | -- | -- | S  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 11 | -- | -- | -- | T  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 12 | -- | -- | -- | -- | A  | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 13 | -- | -- | -- | -- | -- | V  | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 14 | -- | -- | -- | -- | -- | -- | N  | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 15 | -- | -- | -- | -- | -- | -- | Q  | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 16 | -- | -- | -- | -- | -- | -- | S  | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 17 | -- | -- | -- | -- | -- | -- | T  | -- | -- | -- | -- | -- | -- | -- | -- |
| APL 18 | -- | -- | -- | -- | -- | -- | -- | N  | -- | -- | -- | -- | -- | -- | -- |
| APL 19 | -- | -- | -- | -- | -- | -- | -- | Q  | -- | -- | -- | -- | -- | -- | -- |
| APL 20 | -- | -- | -- | -- | -- | -- | -- | S  | -- | -- | -- | -- | -- | -- | -- |

The MHC binding sites exist at glucose-6-phosphate isomerase (GPI) 328 (I), GPI 331 (F) and GPI 334 (E) as indicated (underlined). The amino acid residues of the T-cell receptor contact sites at P0 (Y327), P2 (N329), P3 (C330), P5 (G332), P6 (C333), and P8 (T335) were substituted for the indicated peptides to design 20 types of altered peptide ligands (APLs).
arthritis. First, we immunized DBA/1 mice with each APL alone, and confirmed that no overt arthritis developed (data not shown). DBA/1 mice were then co-immunized with hGPI325-339 and each APL to explore the development of arthritis. Mice co-immunized with APL 6, APL 12 and APL 13 developed significantly attenuated arthritis after day 12, and those co-immunized with APL 7 after day 16, compared with mice immunized with hGPI325-339 alone (P < 0.05) (Figure 2, upper panel). Co-immunization with APL 13 also significantly suppressed the incidence of arthritis (P < 0.05) (Table 2). Co-immunization with hGPI325-339 and APL 15, an agonistic APL, however, did not affect the severity or course of arthritis (Figure 2, middle panel). Moreover, mice co-immunized with hGPI325-339 and OVA323-339 also had a similar course of arthritis to hGPI325-339 alone (Figure 2, lower panel).

Identification of TCRVβ usage of hGPI325-339-specific Th17 cells
To investigate the inhibitory mechanisms of the antagonistic APLs, we explored TCRVβ usage of hGPI325-339-specific CD4+ T cells. The CD4+ T cells primed with hGPI325-339 were stimulated with hGPI325-339 in vitro and the TCRVβ repertoire was analyzed by flow cytometry and compared with that before stimulation. Stimulation with hGPI325-339 expanded the population of CD4+ T cells with TCRVβ8.1 8.2 following stimulation with hGPI325-339 (Figure 3b). These data indicate that many hGPI325-339-specific Th17 cells use TCRVβ8.1 8.2.

Effect of antagonistic altered peptide ligands on differentiation of Th17 and regulatory T cells
In vitro analysis showed that the antagonistic APLs suppressed IL-17 production, and that co-immunization with the APLs inhibited the development of arthritis. We therefore explored the effect of APLs on Th17 differentiation. Our previous report suggested that cross-reactivity of CD4+ T cells primed with hGPI325-339 to mGPI325-339 was critical for the development of arthritis. We therefore assessed the population of mGPI325-339-reactive Th17 cells in the DLNs of mice co-

Available online http://arthritis-research.com/content/11/6/R167
immunized with each APL. IL-17 production by CD4+ T cells with TCRVβ8.1 8.2 or other TCRVβ with stimulation of mGPI325-339 was not affected by co-immunization with APLs (Figure 4a), and neither was affected IL-17 production with hGPI325-339 (data not shown). Unexpectedly, IL-17 production was considerable with stimulation of the corresponding APLs (Figure 4b). ELISA showed undetectable levels of IL-4, and the IL-10 production, and IFNγ production was not affected (data not shown). Co-immunization with APLs did not affect the population of regulatory T cells nor the expression of CD25 (Figure 5), and stimulation of DLN cells of co-immunized mice with APLs in vitro did not induce the expansion of regulatory T cells (data not shown).

Identification of TCRVβ usage of altered peptide ligand-specific CD4+ T cells

The unexpected data mentioned above suggested that APL-specific CD4+ T cells were developed by co-immunization. We
Effects of co-immunization with altered peptide ligands on the development of arthritis

| Co-immunization | Incidence | Day of onset | Maximum severity |
|-----------------|-----------|-------------|-----------------|
| None            | 8/8       | 10 ± 0.0    | 10.9 ± 1.4      |
| APL 6           | 8/8       | 10 ± 0.0    | 7.5 ± 2.0**     |
| APL 7           | 6/8       | 10 ± 0.0    | 7.8 ± 1.7*      |
| APL 12          | 7/8       | 10.3 ± 0.8  | 5.0 ± 1.2**     |
| APL 13          | 3/8†      | 10 ± 0.0    | 4.0 ± 0.0**     |

Mice were co-immunized with 10 μg glucose-6-phosphate isomerase hGPI325-339 and 50 μg indicated antigen. Data presented as incidence or mean ± standard deviation. *P < 0.05 (Fisher's exact test). **P < 0.001 (Mann–Whitney U test).

Discussion

APLs are considered useful for antigen-specific therapy of autoimmune diseases and allergy. Treatments with APLs have so far been tested in several autoimmune models, and especially experimental autoimmune encephalitis has been enthusiastically examined for APLs designed as a single amino acid substitution of a TCR contact site. In experimental autoimmune encephalitis in Lewis rats, co-immunization with the APL (K91A) of myelin basic protein MBP87-99 strongly inhibited the development of the disease by suppression of IFNγ and TNFα, not T-cell proliferation [31]. Furthermore, another study of experimental autoimmune encephalitis in SJL mice showed that co-immunization with the APL (W144Q) of myelin proteolipid protein PLP139-151 also inhibited the disease, and that the T-cell clone specific for the APL (W144Q) possessed the Th0 or Th2 phenotype [32].

Although one study used conventional APLs in collagen-induced arthritis [33], unconventional APLs with substitutions at MHC binding sites were mainly tested in arthritis models. Myers and colleagues reported that the analog peptide (I260A, A261B(hydroxyproline), F263N) significantly suppressed collagen-induced arthritis by inducing Th2 cells in DBA/1 mice [34]. They also reported the suppression of collagen-induced arthritis in HLA-DR1 and HLA-DR4 transgenic mice using other analog peptides with substitutions at MHC binding sites [35,36]. Another group reported also that the antigen-specific proinflammatory response to the human cartilage glycoprotein-39 (263 to 275) epitope was suppressed in DR4 transgenic mice by APLs with substitution at MHC binding sites [37].

In our study, we designed various APLs (N329S, N329T, G332A, or G332V) of hGPI325-339 with substitutions at TCR contact sites, and showed that co-immunization with the individual APL significantly inhibited the development of arthritis. Although the APLs had antagonism to Th17 primed with hGPI cells in vitro (Figure 1), analysis of the mechanisms of the effect of co-immunizing APLs showed normal development of hGPI325-339-specific Th17 cells and APL-specific Th17 cells in vivo (Figure 4). Co-immunization with hGPI325-339 and the APL might have induced both hGPI325-339-specific Th17 clones and APL-specific Th17 clones by the adjuvant effects of complete Freund’s adjuvant and pertussis toxin.

Since both the TCR signal and the co-stimulatory signal are essential for priming of naïve T cells, our data suggested the potency of the APLs as agonists to some TCRs. It is likely that...
an antigen acts as an agonist to one T-cell clone and as an antagonist to another T-cell clone because any TCR can cross-react with various antigens. Although the antigen specificity is mainly determined by the complementary determining regions, the different ratio of TCRβ usage between hGPI325-339-specific CD4+ T cells and APL-specific CD4+ T cells (especially APL 13) indicates that each CD4+ T cell is a different clone that leads to different antigen specificity, and does not cross-react to the APLs and hGPI325-339 to conduct positive TCR signals, respectively. Our previous paper showed that T cells primed with hGPI325-339 could cross-react to mGPI325-339 and that the cross-reactivity to mGPI325-339 was crucial for induction arthritis [27]. The findings that immunization with the APLs (APL 6, APL 7, APL 12, APL 13) alone

Figure 3

Human glucose-6-phosphate isomerase-specific Th17 cells use TCRβ8.1 8.2. Many glucose-6-phosphate isomerase hGPI325-339-specific Th17 cells use TCRβ8.1 8.2. Mice were immunized with 10 μg hGPI325-339, and draining lymph node cells on day 6 were stimulated with 20 μM hGPI325-339 for 72 hours, and after stimulation. (b) GoldStop was added in the last 4 hours of the 24-hour culture. Flow cytometry analysis for IL-17 was gated in CD4high cells. Representative data of two independent experiments.
Co-immunization with altered peptide ligands does not affect IL-17 production. Mice were immunized with 10 μg glucose-6-phosphate isomerase hGPI325–339 and 50 μg each altered peptide ligand (APL). Draining lymph node cells on day 6 were stimulated for 24 hours in vitro (a) with 10 μM mouse GPI325–339 or (b) with 10 μM corresponding APL. GoldiStop was added in the last 4 hours of each culture. Flow cytometry analysis for IL-17 and TCRVβ repertoire was gated in CD4<sup>high</sup> cells. None, immunization with no APL (hGPI<sub>325–339</sub> alone). Representative flow cytometry data of two independent experiments.
Co-immunization with altered peptide ligands neither induces regulatory T cells nor modulates CD25 expression. Mice were immunized with 10 μg glucose-6-phosphate isomerase hGPI\textsubscript{325--339} and 50 μg each altered peptide ligand (APL), and draining lymph node cells on day 6 were stained with Foxp3 and CD25. Flow cytometry analysis was gated in CD4\textsuperscript{+} cells. None, immunization with no APL (hGPI\textsubscript{325--339} alone). Representative flow cytometry data of two independent experiments.

could not induce any overt arthritis indicated that APL-specific T cells could not cross-react mGPI\textsubscript{325--339} suggesting they do not have potential for induction of arthritis.

One of the inhibitory mechanisms of APL is anergy. Allen and colleagues reported that APL could induce anergy of T-cell clones by partial activation [38], which was characterized by an increase in cell volume and upregulation of CD25, without cytokine production or cell proliferation. Another mechanism is induction of anti-inflammatory T-cell lineages such as Th2/Th0 as well as regulatory T cells. Nicholson and colleagues reported that co-immunization with PLP\textsubscript{139--151} and APL (W144L/H147R) did not inhibit the induction of PLP\textsubscript{139--151}\textsuperscript{*} specific T cells, but induced APL-specific Th2/Th0 phenotype cells to suppress the progression of experimental autoimmune encephalitis by stander suppression [39].

| coimmunization | none | APL 6 | APL 7 | APL 12 | APL 13 |
|----------------|------|-------|-------|--------|--------|
| none           | 15.3 | 13.6  | 12.8  | 10.9   | 12.6   |
| CD4            | 2.18 | 2.04  | 1.82  | 1.39   | 1.74   |
| Foxp3          | 11.2 | 11.3  | 11.9  | 10.6   | 11.3   |
| TCRVβ8.1       | 8.1  | 8.2   |       |        |        |
| CD25           |      |       |       |        |        |
| CD4            |      |       |       |        |        |
In our system, however, neither of these mechanisms was likely because the APLs did not inhibit IL-17 production and cell proliferation with stimulation of mGPI325-339, and induction of any anti-inflammatory and regulatory T cells was not detected. Nevertheless, it is probable that APLs inhibit mGPI325-339-specific T cells because our analysis showed significant reductions of anti-mGP Abs, which were Abs to thymus-dependent antigen [26]. We assumed that competitive bindings of APL to TCR in vivo were likely in our system; however, it cannot be denied that amino acid substitutions in peptides, even those that are not directly involved in MHC binding, might affect the overall structure of the peptide and binding affinity to MHC. Taken together, competitive binding of the APLs to hGPI325-339-specific TCR or MHC in vivo is considered most likely as an inhibitory mechanism of APLs in our system.

The major interest in APLs is their clinical application; several studies showed that APLs suppress autoreactive cells in RA and Sjogren’s syndrome [40,41]. Although clinical trials of APL in RA have not yet been conducted, phase II clinical trials in multiple sclerosis have been reported [42,43]. In one study.
of eight patients with multiple sclerosis, subcutaneous administration at 50 mg dose once-weekly of CGP77116 - an APL with substitutions at multiple TCR contact sites of MBP83-99 - resulted in the development of exacerbations in two patients with enhancement of MBP83-99-reactive Th1 response [42]. Another double-blind placebo-controlled clinical trial included 142 patients who received various doses of subcutaneously injected NBI5788, an APL of MBP83-99 with substitutions at TCR contact sites [43]. In contrast to the former study, the administration of 5 mg APL weekly significantly decreased inflammatory lesions in the central nervous system. Unfortunately, the study was halted because 9% of the patients developed hypersensitivity reactions, but none discontinued at a dose of 5 mg in the double-blind phase whereas all patients discontinued in the double-blind phase after receiving higher doses of 20 or 50 mg. Low-dose APLs might therefore be useful agents for antigen-specific therapies of autoimmune diseases including RA, and their efficacy in RA might be more promising than in multiple sclerosis because drugs can be injected directly into the inflammatory lesions.

Co-immunization with altered peptide ligands suppresses production of antibodies to mouse glucose-6-phosphate isomerase. Sera were taken on day 28 from mice co-immunized with 10 μg glucose-6-phosphate isomerase hGPI325--339 and 50 μg each altered peptide ligand (APL), and the titers of anti-mouse GPI IgG and IgG isotype were analyzed by ELISA. Each symbol represents a single mouse. Data presented as mean optimal density ± standard deviation. *P < 0.01, **P < 0.005, ***P < 0.001 (Mann–Whitney U test).
Finally, can GPI be a target of antigen-specific therapies in RA? It has been reported that patients with severe forms of RA retained high titers of anti-GPI Abs [44-47] and GPI-reactive CD4+ T cells were detected among anti-GPI-Ab-positive patients with RA [48]. These findings highlight autoimmune responses to GPI are occurring in some patients with RA, and GPI could be a target of antigen-specific therapies to them - although further studies are needed to clarify the exact pathological role of GPI in RA.

Conclusions

The results of the present study showed that APLs with substitutions at TCR contact sites inhibit GPI peptide-induced arthritis. Novel antigen-specific therapies based on APLs may prove beneficial in arthritis induced by autoimmune responses to autoantigens.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

KI wrote the manuscript and conducted all experiments. YY, AI, KY YT, and RM assisted in the completion of the experiments. TS designed and coordinated the study. IM coordinated and directed the study. YN designed the APLs and provided advice for the study. TH, DG and SI participated in the discussion.

Acknowledgements

The present work was supported in part by a grant from The Japanese Ministry of Science and Culture (IM, TS).

References

1. Struyk L, Hawes GE, Chatila MK, Breedveld FC, Kunick JT, Elen PJ van den: ‘T cell receptors in rheumatoid arthritis.’ Arthritis Rheum 1995, 38:577-589.

2. Kremer JM, Westhoven's R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Naumah H, Williams GR, Roossinck J, Joosten LA, Berg WB van den: ‘Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.’ Am J Pathol 2005, 167:141-149.

3. Nakae S, Saito S, Morita T, Izawa T, Tsuchimoto K, Tsuchiya M, Ota S, Kishimoto T, Inoue T, Suematsu M, Ousaka Y, Hori, and Tomiyama H: ‘Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice.’ J Immunol 2003, 171:6173-6177.

4. Iwami K, Matsutomo I, Tanaka-Watanabe Y, Mihara M, Ohigashi Y, Yamamura M, Goto D, Ito S, Tsutsumi A, Kishimoto T, Sumida T: ‘Crucial role of IL-6/IL-17 axis in the induction of arthritis by glucose-6-phosphate isomerase.’ Arthritis Rheum 2008, 58:754-763.

5. Koenders MI, Lubberts E, Oppers-Walgren B, Berseelaar L van den, Helsen MM, Di Padova PE, Boots AMH, Gram H, Joosten

LAB, Berg WB van den: ‘Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.’ Am J Pathol 2005, 167:141-149.

6. Nakae S, Saito S, Morita T, Izawa T, Tsuchimoto K, Tsuchiya M, Ota S, Kishimoto T, Inoue T, Suematsu M, Ousaka Y, Hori, and Tomiyama H: ‘Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice.’ J Immunol 2003, 171:6173-6177.

7. Iwami K, Matsutomo I, Tanaka-Watanabe Y, Mihara M, Ohigashi Y, Yamamura M, Goto D, Ito S, Tsutsumi A, Kishimoto T, Sumida T: ‘Crucial role of IL-6/IL-17 axis in the induction of arthritis by glucose-6-phosphate isomerase.’ Arthritis Rheum 2008, 58:754-763.

8. Koenders MI, Lubberts E, Oppers-Walgren B, Berseelaar L van den, Helsen MM, Di Padova PE, Boots AMH, Gram H, Joosten

Available online http://arthritis-research.org/content/11/6/R167

(page number not for citation purposes)
24. Rosloniec EF, Whittington KB, Brand DD, Myers LK, Stuart JM: Identification of MHC class II and TCR binding residues in the type II collagen immunodominant determinant mediating collagen-induced arthritis. *Cell Immunol* 1996, 172:21-28.

25. Bayrak Ş, Holmdahl R, Travers P, Lauster R, Hesse M, Dölling R, Mitchison NA: T cell response of I-A*-mice to self type II collagen: meshing of the binding motif of the I-A* molecule with repetitive sequences results in autoactivity to multiple epitopes. *Int Immunol* 1997, 9:1687-1699.

26. Schubert D, Maier B, Morawietz L, Krenn V, Kamradt T: Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in generally unaltered mice. *J Immunol* 2004, 172:4503-4509.

27. Iwamani K, Matsumoto I, Tanaka Y, Goto D, Ito S, Tsutsumi A, Sumida T: Arthritisigenic T cell epitope in glucose-6-phosphate isomerase-induced arthritis. *Arthritis Res Ther* 2008, 10:R130.

28. Matsumoto I, Lee DM, Goldbach-Mansky R, Sumida T, Ishii van CA, Schur PH, Anderson RJ, Coblyn JS, Weinblatt ME, Brenner M, Duclos B, Pasquali JL, El-Gabalawy H, Mathis D, Benoist C: Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. *Arthritis Rheum* 2003, 48:944-954.

29. Matsumoto I, Staub A, Benoist C, Mathis D: Arthritis provoked by linked T and B recognition of a glycolytic enzyme. *Science* 1999, 286:1732-1735.

30. De Magistris MT, Alexander J, Coggeshall M, Altman A, Gaeta CA, Schur PH, Anderson RJ, Coblyn JS, Weinblatt ME, Brenner M, Duclos B, Pasquali JL, El-Gabalawy H, Mathis D, Benoist C: Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. *Arthritis Rheum* 2003, 48:944-954.

31. Mitchell DJ, Brocke S, Ling N, Steinman L: Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis in mice. *Mod Rheumatol* 2009, 19:366-371.

32. Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, Kang AH: Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. *J Immunol* 1998, 161:3589-3595.

33. Myers LK, Sakurai Y, Tang B, He X, Rosloniec EF, Stuart JM, Kang AH: Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice. *Arthritis Rheum* 2002, 46:3369-3377.

34. Sakurai Y, Brand DD, Tang B, Rosloniec EF, Stuart JM, Kang AH, Myers LK: Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. *Arthritis Res Ther* 2006, 8:R150.

35. Boots AMH, Huberts H, Kowijzer M, den Hoed-van Zandbrink L, Wiersma-Esseveld M, van de Walt J, Stenger R, Boe EJ, Lierop MC, Verheijden GF, Timmers CM, van Staveren CJ: Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39 (263-275) epitope: an MHC anchor variant peptide for immune modulation. *Arthritis Res Ther* 2007, 9:R71.

36. Sloan-Lancaster J, Evavold BD, Allen PM: Induction of T-cell anergy by altered T-cell receptor ligand on live antigen-presenting cells. *Nature* 1993, 363:156-159.

37. Nicholson LB, Murtaza A, Hafler BP, Sette A, Kuchroo VJ: A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. *Proc Natl Acad Sci USA* 1997, 94:9279-9284.

38. Ohnishi Y, Tsutsuji A, Matsumoto I, Goto D, Ito S, Kusama N, Jumura Y, Nishimura Y, Sumida T: Altered peptide ligand control type II collagen-reactive T cells from rheumatoid arthritis patients. *Mod Rheumatol* 2006, 16:226-228.

39. Naito Y, Matsumoto I, Waka-matsu E, Goto D, Ito S, Tsutsumi A, Sumida T: Altered peptide ligands regulate muscarinic acetylcholine receptor reactive T cells of patients with Sjogren's syndrome. *Ann Rheum Dis* 2006, 65:269-271.

40. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afahar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. *Nat Med* 2000, 6:1167-1175.

41. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L, The Altered Peptide Ligand in Relapsing MS Study Group: Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. *Nat Med* 2000, 6:1176-1182.

42. Matsumoto I, Lee DM, Goldbach-Mansky R, Sumida T, Hitchon CA, Schur PH, Anderson RJ, Coblyn JS, Weinblatt ME, Brenner M, Duclos B, Pasquali JL, El-Gabalawy H, Mathis D, Benoist C: Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. *Arthritis Rheum* 2003, 48:944-954.

43. Kassahn D, Kolb C, Solomon S, Bochtler P, Illges H: Few human autoimmune sera detect GPI. *Nat Immunol* 2002, 3:411-412.

44. Schubert D, Schmidt M, Zais D, Jungblut PR, Kamradt T: Autoantibodies to GPI and creatine kinase in RA. *Nat Immunol* 2002, 3:411.